A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
via Google News
The Latest on: Retinitis pigmentosa
- FDA grants rare pediatric disease designation for QR-421a in retinitis pigmentosaon January 31, 2020 at 11:04 am
QR-421a has received rare pediatric disease designation from the FDA for the treatment of retinitis pigmentosa, according to a press release from ProQR Therapeutics. QR-421a, an RNA-based ...
- Exclusive: Applied Genetic's CEO Talks Partnerships, Politics, Pipelineon January 31, 2020 at 4:20 am
In the last year, sell-side analysts have shown confidence in Applied Genetic Technologies Corp AGTC with a series of upgrades and initiations. BMO, Chardan, Janney and Roth all bought into the ...
- Retinitis Pigmentosa Due to Rp1 Biallelic Variantson January 31, 2020 at 2:44 am
A total of seven unrelated and nonsyndromic patients with RP1 biallelic variants (OMIM # 180100) were diagnosed in our centre and included in the study. They had classic retinitis pigmentosa with ...
- Meet Charlie Mitchell, D.C. patent attorney and blind Team USA hockey playeron January 28, 2020 at 8:36 am
Charlie Mitchell, a D.C. patent attorney, was resigned to the fact that he would never play hockey again when he was informed his vision would progressively deteriorate. Then he found the Washington ...
- BRIEF-AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial In X-Linked Retinitis Pigmentosaon January 9, 2020 at 6:50 am
Jan 9 (Reuters) - Applied Genetic Technologies Corp : * AGTC REPORTS POSITIVE SIX-MONTH DATA FROM ITS ONGOING PHASE 1/2 CLINICAL TRIAL IN X-LINKED RETINITIS PIGMENTOSA * APPLIED GENETIC ...
- AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosaon January 9, 2020 at 4:09 am
Its initial focus is in the field of ophthalmology, in which it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its ...
- Retinitis Pigmentosa (RP) Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025on January 6, 2020 at 11:28 pm
Jan 07, 2020 (The Expresswire) -- Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady ...
via Bing News